LMATNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
LEMAITRE VASCULAR INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.31+1.49 (+1.84%)
Close on Oct 19, 2026
- Market cap
- $2.02B
- P/E (TTM)
- 28.9
- Dividend yield
- 0.97%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
71.5%+6.1 pts over 5 years
Operating margin
27.2%+5.0 pts over 5 years
Net margin
23.1%+6.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +13.5% | +15.6% | +14.0% | +12.3% | |
| Gross profit | +18.3% | +19.4% | +16.1% | +12.7% | |
| Operating income | +30.0% | +36.3% | +18.7% | +19.4% | |
| Net income | +31.1% | +40.9% | +22.2% | +22.2% | |
| EPS, diluted | +30.6% | +39.4% | +19.4% | +19.6% | |
| Free cash flow | +100.4% | +49.8% | +18.5% | +23.3% | |
| Dividend per share | +25.0% | +17.0% | +16.1% | +17.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 12.8% | 13.2% | 15.8% | |
| Return on assets | 11.0% | 9.6% | 9.9% | |
| Current ratio | 5.63 | 3.75 | 12.89 | |
| Interest coverage | 1166.9× | 22.0× | 13.1× | |
| Capex to revenue | 3.2% | 2.3% | 2.7% | |
| Diluted shares | 19M | 20M | 23M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lemaitre Vascular generated $222.61M from operations and spent $100.22M on capital expenditure, dividends and share buybacks. 29% of that went back into the business.
Generated
$222.61M
Used
$100.22M
Capital expenditure$29.12M29%Dividends$65.26M65%Share buybacks$5.84M6%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin23.1%
×Asset turnover0.43×
×Equity multiplier1.60×
=Return on equity, FY202515.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 23.1% | 0.43× | 1.60× | 15.8% |
| FY2024 | 20.0% | 0.49× | 1.41× | 13.9% |
| FY2023 | 15.6% | 0.59× | 1.16× | 10.6% |
| FY2022 | 12.8% | 0.54× | 1.15× | 7.9% |
| FY2021 | 17.4% | 0.57× | 1.28× | 12.6% |
| FY2020 | 16.4% | 0.59× | 1.38× | 13.2% |
| FY2019 | 15.3% | 0.69× | 1.23× | 12.9% |
| FY2018 | 21.7% | 0.76× | 1.16× | 19.1% |
| FY2017 | 17.0% | 0.88× | 1.16× | 17.4% |
| FY2016 | 11.9% | 0.93× | 1.16× | 12.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$57.73M
- Cash generatingOperating cash flow above zero$81.25M
- Return on assets improvedROA up on the prior year12.7% → 10.5%
- Earnings backed by cashOperating cash flow above net income$81.25M vs $57.73M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose13.14 → 12.89
- No dilutionShare count did not rise23M → 23M
- Gross margin improvedGross margin up on the prior year68.63% → 71.53%
- More efficientAsset turnover rose0.63 → 0.45